DTIL

Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.

Wall Street analysts forecast DTIL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DTIL is 45.00 USD with a low forecast of 30.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Precision BioSciences Inc revenue for the last quarter amounts to 13.00K USD, decreased -97.74 % YoY.

Precision BioSciences Inc. EPS for the last quarter amounts to -1.84 USD, decreased -18.22 % YoY.

Precision BioSciences Inc (DTIL) has 108 emplpoyees as of December 15 2025.

Today DTIL has the market capitalization of 120.12M USD.